DK4541379T3 - Stabile koncentrerede radionuklidkompleksopløsninger - Google Patents

Stabile koncentrerede radionuklidkompleksopløsninger

Info

Publication number
DK4541379T3
DK4541379T3 DK25162390.6T DK25162390T DK4541379T3 DK 4541379 T3 DK4541379 T3 DK 4541379T3 DK 25162390 T DK25162390 T DK 25162390T DK 4541379 T3 DK4541379 T3 DK 4541379T3
Authority
DK
Denmark
Prior art keywords
complex solutions
stable concentrated
radionuclide complex
concentrated radionuclide
stable
Prior art date
Application number
DK25162390.6T
Other languages
English (en)
Inventor
Daniela Chicco
Donato Barbato
Palo Francesco De
Lorenza Fugazza
Maurizio Mariani
Giovanni Tesoriere
Clementina Brambati
Original Assignee
Advanced Accelerator Applications S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63794577&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK4541379(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2018/055575 external-priority patent/WO2020021310A1/en
Priority claimed from US16/045,484 external-priority patent/US20200030465A1/en
Application filed by Advanced Accelerator Applications S A filed Critical Advanced Accelerator Applications S A
Application granted granted Critical
Publication of DK4541379T3 publication Critical patent/DK4541379T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A61K51/048DTPA (diethylenetriamine tetraacetic acid)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121Solutions, i.e. homogeneous liquid formulation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DK25162390.6T 2018-07-25 2018-09-25 Stabile koncentrerede radionuklidkompleksopløsninger DK4541379T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/IB2018/055575 WO2020021310A1 (en) 2018-07-25 2018-07-25 Stable, concentrated radionuclide complex solutions
US16/045,484 US20200030465A1 (en) 2018-07-25 2018-07-25 Stable, concentrated radionuclide complex solutions
EP18783136.7A EP3826686B1 (en) 2018-07-25 2018-09-25 Stable, concentrated radionuclide complex solutions

Publications (1)

Publication Number Publication Date
DK4541379T3 true DK4541379T3 (da) 2026-02-02

Family

ID=63794577

Family Applications (6)

Application Number Title Priority Date Filing Date
DK25162396.3T DK4545101T3 (da) 2018-07-25 2018-09-25 Stabile koncentrerede radionuklidkompleksopløsninger
DK25162394.8T DK4545100T3 (da) 2018-07-25 2018-09-25 Stabile koncentrerede radionuklidkompleksopløsninger
DK18783136.7T DK3826686T3 (da) 2018-07-25 2018-09-25 Stabile koncentrerede radionuklidkompleksopløsninger
DK25162403.7T DK4541381T3 (da) 2018-07-25 2018-09-25 Stabile koncentrerede radionuklid-kompleksopløsninger
DK25162391.4T DK4541380T3 (da) 2018-07-25 2018-09-25 Stabile koncentrerede radionuklidkompleksopløsninger
DK25162390.6T DK4541379T3 (da) 2018-07-25 2018-09-25 Stabile koncentrerede radionuklidkompleksopløsninger

Family Applications Before (5)

Application Number Title Priority Date Filing Date
DK25162396.3T DK4545101T3 (da) 2018-07-25 2018-09-25 Stabile koncentrerede radionuklidkompleksopløsninger
DK25162394.8T DK4545100T3 (da) 2018-07-25 2018-09-25 Stabile koncentrerede radionuklidkompleksopløsninger
DK18783136.7T DK3826686T3 (da) 2018-07-25 2018-09-25 Stabile koncentrerede radionuklidkompleksopløsninger
DK25162403.7T DK4541381T3 (da) 2018-07-25 2018-09-25 Stabile koncentrerede radionuklid-kompleksopløsninger
DK25162391.4T DK4541380T3 (da) 2018-07-25 2018-09-25 Stabile koncentrerede radionuklidkompleksopløsninger

Country Status (23)

Country Link
EP (7) EP4541380B1 (da)
JP (3) JP7402218B2 (da)
KR (4) KR102865113B1 (da)
CN (5) CN120860272A (da)
AU (6) AU2018433575B2 (da)
BR (1) BR112021001148A2 (da)
CA (1) CA3153630A1 (da)
CO (1) CO2021000506A2 (da)
DE (3) DE202018007007U1 (da)
DK (6) DK4545101T3 (da)
ES (5) ES3038413T3 (da)
FI (6) FI4541380T3 (da)
HR (6) HRP20260100T1 (da)
HU (1) HUE072720T2 (da)
IL (5) IL319541B2 (da)
LT (6) LT4545101T (da)
MX (2) MX2021000805A (da)
PL (6) PL3826686T3 (da)
PT (6) PT4541381T (da)
RS (6) RS67755B1 (da)
SG (1) SG11202100645XA (da)
SI (5) SI4545101T1 (da)
WO (1) WO2020021322A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
US20250032652A1 (en) * 2021-11-30 2025-01-30 Nihon Medi-Physics Co., Ltd. Stabilized radiopharmaceutical composition
CN118159303A (zh) * 2022-02-04 2024-06-07 先进加速器应用公司 用于大规模合成放射性核素络合物的方法
CN114404618A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其用途
CN114404619A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
CN116920129A (zh) * 2022-04-02 2023-10-24 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
US20260102526A1 (en) * 2024-06-27 2026-04-16 Curium Us Llc 177lutetium-dota-tate formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US6066309A (en) * 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
IL143236A0 (en) 1998-12-16 2002-04-21 Warner Lambert Co Treatment of arthritis with mek inhibitors
WO2002006213A2 (en) 2000-07-19 2002-01-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
BR0307544A (pt) 2002-02-01 2004-12-07 Ariad Gene Therapeutics Inc Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
US7799827B2 (en) 2002-03-08 2010-09-21 Eisai Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
TWI343377B (en) 2002-03-13 2011-06-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
SG177216A1 (en) * 2003-07-24 2012-01-30 Bracco Imaging Spa Stable radiopharmaceutical compositions and methods for their preparation
WO2007014011A2 (en) 2005-07-21 2007-02-01 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
WO2008009444A1 (en) 2006-07-19 2008-01-24 Van Dulmen, Adrianus, A. Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide
CA3042737A1 (en) * 2016-11-04 2018-05-11 Clarity Pharmaceuticals Pty Ltd Formulations for radiotherapy and diagnostic imaging
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions

Also Published As

Publication number Publication date
LT3826686T (lt) 2025-08-25
IL313560B2 (en) 2025-11-01
AU2025220852A1 (en) 2025-09-11
SG11202100645XA (en) 2021-02-25
EP4541381B1 (en) 2026-02-04
EP4541379A3 (en) 2025-07-23
JP2025111424A (ja) 2025-07-30
LT4541379T (lt) 2026-02-10
AU2025204901A1 (en) 2025-07-17
DK3826686T3 (da) 2025-08-25
AU2022203683A1 (en) 2022-06-16
HRP20260338T1 (hr) 2026-04-10
MX2021000805A (es) 2021-05-12
AU2024201217B2 (en) 2025-02-27
EP4640241A2 (en) 2025-10-29
WO2020021322A1 (en) 2020-01-30
AU2025202231A1 (en) 2025-04-17
LT4541381T (lt) 2026-03-25
SI4545101T1 (sl) 2026-04-30
ES3063402T3 (en) 2026-04-16
PL4541380T3 (pl) 2026-03-30
FI4541379T3 (fi) 2026-02-17
FI3826686T3 (fi) 2025-08-20
LT4545100T (lt) 2026-02-25
PT4541379T (pt) 2026-01-29
KR20250017751A (ko) 2025-02-04
FI4541380T3 (fi) 2026-03-02
CN112584875A (zh) 2021-03-30
IL319542A (en) 2025-05-01
IL326944A (en) 2026-05-01
AU2022203683B2 (en) 2023-12-21
EP4640241A3 (en) 2025-12-10
ES3038413T3 (en) 2025-10-13
DK4541381T3 (da) 2026-04-07
CN121081692A (zh) 2025-12-09
CN120860270A (zh) 2025-10-31
KR102643582B1 (ko) 2024-03-05
JP7796696B2 (ja) 2026-01-09
EP4541380A3 (en) 2025-07-23
HRP20250912T1 (hr) 2025-09-26
FI4541381T3 (fi) 2026-04-01
PL4541379T3 (pl) 2026-03-23
KR20240033296A (ko) 2024-03-12
PT4541381T (pt) 2026-03-17
EP4541381A2 (en) 2025-04-23
EP4541379B1 (en) 2025-11-19
PL3826686T3 (pl) 2025-09-22
IL319541B2 (en) 2026-01-01
PL4541381T3 (pl) 2026-05-11
PT4545101T (pt) 2026-02-24
DE202018006567U1 (de) 2021-04-01
AU2025202231B2 (en) 2026-05-14
DE202018007006U1 (de) 2025-11-13
PL4545101T3 (pl) 2026-03-30
IL313560A (en) 2024-08-01
AU2025220852B2 (en) 2025-10-23
DK4545101T3 (da) 2026-03-02
CO2021000506A2 (es) 2021-04-19
RS67864B1 (sr) 2026-04-30
PT4541380T (pt) 2026-02-24
SI4545100T1 (sl) 2026-03-31
PL4545100T3 (pl) 2026-03-30
AU2024201217A1 (en) 2024-03-14
SI3826686T1 (sl) 2025-09-30
PT3826686T (pt) 2025-08-04
LT4545101T (lt) 2026-03-10
HUE072720T2 (hu) 2025-12-28
EP4545101A2 (en) 2025-04-30
CN120860271A (zh) 2025-10-31
KR20260030955A (ko) 2026-03-06
RS67034B1 (sr) 2025-08-29
BR112021001148A2 (pt) 2021-04-20
JP7402218B2 (ja) 2023-12-20
AU2018433575B2 (en) 2022-07-07
AU2018433575A1 (en) 2021-02-11
IL319541B1 (en) 2025-09-01
SI4541380T1 (sl) 2026-04-30
HRP20260179T1 (hr) 2026-04-10
RS67754B1 (sr) 2026-03-31
IL313560B1 (en) 2025-07-01
FI4545101T3 (fi) 2026-02-24
EP4545101A3 (en) 2025-07-23
DK4545100T3 (da) 2026-02-23
DE202018007007U1 (de) 2025-11-13
JP2023117417A (ja) 2023-08-23
EP4541380B1 (en) 2025-12-10
EP4541381A3 (en) 2025-07-23
PT4545100T (pt) 2026-02-16
EP3826686B1 (en) 2025-05-21
HRP20260222T1 (hr) 2026-03-27
HRP20260100T1 (hr) 2026-04-10
ES3064589T3 (en) 2026-04-27
CN120860272A (zh) 2025-10-31
IL280314A (en) 2021-03-25
RS67667B1 (sr) 2026-02-27
IL319541A (en) 2025-05-01
RS67755B1 (sr) 2026-03-31
IL319542B1 (en) 2026-04-01
ES3064434T3 (en) 2026-04-24
AU2025204901B2 (en) 2025-09-18
EP4545100A2 (en) 2025-04-30
SI4541379T1 (sl) 2026-03-31
FI4545100T3 (fi) 2026-03-02
EP4541379A2 (en) 2025-04-23
EP4545100B1 (en) 2025-12-10
MX2025012060A (es) 2025-11-03
LT4541380T (lt) 2026-03-10
CA3153630A1 (en) 2020-01-30
KR102932818B1 (ko) 2026-03-03
DK4541380T3 (da) 2026-02-23
HRP20260237T1 (hr) 2026-04-10
ES3065583T3 (en) 2026-05-06
EP3826686A1 (en) 2021-06-02
EP4545100A3 (en) 2025-07-23
EP4541380A2 (en) 2025-04-23
JP2022501313A (ja) 2022-01-06
RS67729B1 (sr) 2026-03-31
EP4545101B1 (en) 2025-12-10
KR20210035855A (ko) 2021-04-01
KR102865113B1 (ko) 2025-09-26

Similar Documents

Publication Publication Date Title
DK4541381T3 (da) Stabile koncentrerede radionuklid-kompleksopløsninger
EP3762274A4 (en) STROLLER
EP3632772A4 (en) STROLLER
EP3512753A4 (en) A stroller
EP3574547C0 (en) WAVEGUIDE ASSEMBLY
EP3401377A4 (en) PHOTOREVERSIBLE LIABILIZER
EP3782874A4 (en) STROLLER
EP3404492A4 (en) CLOCK
EP3672699C0 (en) SPECIAL SCOOTER
EP3519034A4 (en) CHELATING MOLECULES
EP4239631C0 (en) REDUCED-SCALE DECODING
EP3347766C0 (en) OPTICAL AMPLIFIER
EP3853103C0 (de) Kinderwagen
EP3693771A4 (en) OPTOISOLATOR
FR3053267B1 (fr) Pince mecatronique
EP3550383A4 (en) WATCH CASE
DK3476320T3 (da) Intramedullær fikseringsanordning
DE102017206431A8 (de) Brillenbügel
UA40910S (uk) Візок
IT201700101845A1 (it) Astuccio portaocchiali perfezionato
CL2018001851S1 (es) Bicicleta
ES1200436Y (es) Gafas perfeccionadas
CZ32467U1 (cs) Hodiny
DK3348724T3 (da) Forbindelsesstykke
IT201700040519A1 (it) Metronomo ottico.